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ABSTRACT 
This article is to provide a general overview of cancer in China including the statistics, most common cancers, their 
epidemiological characteristics and the treatments. © 2008 Biomedical Imaging and Intervention Journal. All rights 
reserved. 
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CANCER STATISTICS IN CHINA 
The most recent epidemiological data has shown 
that over 2.2 million new cancer cases (1.4 million in 
men, 0.8 million in women) are diagnosed in China each 
year and approximately 1.6 million of the cancers result 
in mortality. Over the last 20 years, the cancer-related 
mortality rate has risen by 30%, which constitutes 25-
35% of all deaths. From 2000 to 2005 alone, the total 
number of new cases increased by 14.6% with the most 
common sites being lung, liver and stomach in men, and 
breast, lung and stomach in women primarily as a result 
of population growth and aging [1]. In addition, the 
rising rates of lung cancer incidence (in both sexes) and 
breast cancer mean that there will be much greater 
increases in the number of cases at these two sites (27% 
for lung cancer in men, 38% for lung and breast cancer 
in women). Cancer has become the number one cause of 
death in China [2]. 
As of the end of 2006, there are 104.2 million 
people who are 65 years or older, constituting 7.9% of 
the entire population in China. At present, China also has 
20% of the world’s population older than 60 years old, 
which has surpassed 150 million. China has become one 
of the aging countries, with the fastest growth and the 
largest aging population in the world. This is one of the 
major reasons for rising cancer incidence in China. 
In urban populations, the leading causes of death are 
as follows; cancer, cerebral vascular accidents, 
cardiovascular, pulmonary, injury and poisoning, 
gastrointestinal, endocrinological and metabolical, 
urological, and psychiatric disorders. Although over the 
last five decades the overall cancer incidence has 
continued to climb, this trend is not observed in all types 
of cancers. What used to be the most common cancers 
such as gastric, cervical, penile, oesophageal and 
nasopharyngeal cancers have declined in various degrees, 
whereas lung, breast, colon, and prostate cancer rates 
have increased significantly (Table 1). This kind of shift 
in cancer rates is more evident in more developed coastal 
cities, which likely is due to the changes in lifestyle and 
diet (Table 2). 
The top five most common malignancies in China 
are lung, liver, gastric, oesophageal and colorectal 
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cancers. The mortality of lung cancer has increased every 
year. For example, in Beijing, lung cancer death 
constitutes one-quarter of all cancer-related mortalities. 
According to the Initiative of Promoting Healthy Living 
in China (Cancer 2006), the mortality rate of lung cancer 
in China may exceed one million by 2025.  
The main reasons for such a high lung cancer 
mortality rate in China are the following: 
●  Lack of awareness of lung cancer 
●  Lack of effective screening tools for early 
detection. Approximately 80% of lung cancers 
in China are advanced stage disease at the 
diagnosis 
●  Lack of access to health care 
●  Lack of health insurance and resources  
●  Lack of scientifically sound comprehensive 
care. It is estimated that about one-third of lung 
cancer patients may have died from inadequate 
or inappropriate therapies in China. 
THE CAUSE AND AETIOLOGY FOR COMMON CANCERS IN 
CHINA 
Lung cancer 
●  Tobacco use and inhalation of second hand 
smoke have clearly become the main causes of 
lung cancer. 
●  Rapid growth of aging population 
●  Rapid industrialisation and westernisation of 
cities 
●  Rapid urbanisation of rural communities 
●  Worsening pollution, especially air and water 
pollution 
●  Unhealthy lifestyles 
The risk factors of lung cancer in China: 
Smoking: China is the largest producer of tobacco 
products in the world; 2.5 times more than that of the 
United States, which is the second largest producer. 
China is also the largest consumer of tobacco in the 
world. The smoker population in China is estimated to be 
over 350 million. As many as 540 million Chinese are 
exposed to second-hand smoke, of which 180 million are 
under the age of 15 years, according to a national 
tobacco control report released on May 29, 2007 by the 
Ministry of Health of China. Women and children are 
most vulnerable to second-hand smoke with the smoking 
rate among men reaching 57%. Ninety percent of the 
women are exposed to second-hand smoke at home. 
There has been no collective effort to curtail the use of 
tobacco products. In 2005, cigarette sales generated 
US$32.5 billion in taxes and profits in China, 
approximately 7.6% of the government's total revenue 
[3]. It is suggested that close to 90% of lung cancer 
mortality is due to cigarette smoking or inhalation of 
second-hand smoke. The link is even stronger in elderly 
smokers. The chance of dying from lung cancer in male 
smokers is eight- to 20-fold that of non-smokers. The 
risk of lung cancer is directly proportionate to the 
amount of cigarettes consumed. The incidence of lung 
cancer is 75 in 10,000 people who smoke less than 14 
cigarettes daily, but this number increases dramatically 
to 227 in smokers who smoke more than 25 cigarettes a 
day. Similarly, the duration of cigarette use also 
proportionately correlates with the risk of developing 
lung cancer. It is an extremely difficult task to control the 
use of cigarettes and to prevent lung cancer in China. 
China has been hit the hardest by tobacco industries with 
more than one million people dying annually of tobacco-
related health problems. If this trend continues, it is 
estimated that over two million people by 2030 and 
possibly three million people by mid-century may die of 
tobacco-related illnesses. By eliminating smoking, it is 
estimated that the total mortality could be reduced by 
10.0% among men and by 3.5% among women in China 
[3].  
Air pollution: China is facing a serious 
environmental crisis due to widespread pollution. Air 
pollution contributes to the high incidence of respiratory 
ailments and lung cancers. The main sources for air 
pollution in China are industrial exhaust and dust, 
automobile exhaust, coal burning for energy, etc., which 
are present mostly in major cities [4, 5].  
Environmental and occupational exposures: 
Occupational exposure to asbestos, silicon, chromium, 
nickel and their by-products are known to cause lung 
cancer. Workers who work at charcoal mills and in the 
mining industries also have a higher risk of lung cancer 
due to chronic exposure to the dust which contains 
silicon, arsenic and radon gas. 
Genetic susceptibility 
Table 1  The Leading Sites of New Cancer Cases in China over 
the last 30 years. 
1970s 1990s 2000s 
Stomach Stomach Lung 
Oesophagus Liver  Liver 
Liver Lung Stomach 
Lung Oesophagus  Oesophagus 
Cervix Colorectal Colorectal 
 
 
Table 2  The percentage of change in annual mortality rates 
among urban and rural areas. 
Type of Cancer  Annual mortality Rate (%) 
 Urban  Rural 
Cervix -27.5  -17.3 
Lung +29.4  +47.7 
Liver +13.0  +17.1 
Colorectal +31.2 +17.5 
Breast +38.9  +39.4 
Bladder +23.5  +19.9 XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   3 
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Liver Cancer-Hepatocellular Carcinoma (HCC) 
The risk factors for liver cancer in China: 
Hepatitis B viral (HBV) infection: Hepatitis B is an 
endemic in China. A national survey in 2002 showed a 
9% rate of hepatitis B surface antigen (HbsAg) in the 
general population [6]. Around 130 million people in 
China are carriers of hepatitis B virus (HBV) (almost a 
third of the people infected with HBV worldwide); 30 
million people in China are chronically infected [7]. 
Every year, 300,000 people die from HBV-related 
diseases in China, including 180,000 patients with HCC 
[8]. The incidence of hepatitis B is still increasing from 
21.9 in 100,000 people in 1990 to 53.3 in 100,000 in 
2003 [9]. That increase has occurred despite a 
vaccination program for newborn babies since the 1990s. 
By 2006, China has successfully immunised 11.1 million 
children living in the country's poorest provinces against 
hepatitis B according to the Chinese health ministry, and 
the Global Alliance for Vaccines and Immunization 
(GAVI). 
Cirrhosis: During a five-year period, 10–20% of 
patients with chronic hepatitis developed cirrhosis, and 
20–23% of the cases with compensated cirrhosis 
progressed to decompensated cirrhosis. Six to 15% of the 
people with cirrhosis and chronic hepatitis progressed to 
HCC. The five-year survival for compensated cirrhosis is 
55%, for decompensated cirrhosis is 14%, and for HCC 
is less than 5%. Approximately 85% of liver cancer 
patients also suffer from cirrhosis, typically nodular type. 
In recent years, hepatitis C related cirrhosis has become 
as prevalent as that of hepatitis B associated cirrhosis. 
Afflatoxins: Afflatoxins B1 (AFB1) is a well-known 
carcinogen for liver cancer. These toxins are made by 
fungus that contaminates peanuts and corn. Once 
ingested, these toxins can cause liver cancer directly or 
enhance the risk from hepatitis B infection.  
Contamination of drinking water: A strong 
association exists between the incidence of liver cancer 
and the consumption of polluted water in rural areas of 
China.  
Alcohol consumption: Excessive drinking of alcohol 
remains a risk factor for HCC. Some studies have also 
shown an increased risk of HCC in those that use alcohol 
and tobacco due to an additive effect.  
Parasite infection: A parasitic worm, commonly 
known as a fluke, infests rivers in rural parts of China. 
Flukes can stimulate proliferation in the epithelium of 
the biliary duct during feeding and migration, which in 
turn can induce cholangiobiliary carcinoma.  
Genetic susceptibility and hereditary 
Gastric cancer and its risk factors 
Dietary: Unhealthy diets and food preparations can 
introduce carcinogens for gastric cancer. The most well-
known substances are nitrates and nitric acid, nitrous 
acid, complex aromatic hydrocarbon and its byproducts. 
These may contaminate the food or can be produced 
during processing of the food, and has been shown to 
increase the risk for stomach cancer as demonstrated in 
some regions in China where smoked fish and meat are 
frequently consumed. There is some evidence to suggest 
a correlation of stomach cancer with diets high in sodium. 
The deficiency in certain nutrients such as animal 
proteins, vitamins and antioxidants may also play a role 
in the development of gastric cancer.  
Infections:  Helicobacter pylori is a well-known 
cause for certain stomach cancers.  
Genetics: A positive family history also increases 
the risk for gastric cancer.  
Oesophageal cancer and its risk factors: 
Chemicals and environmental factors, including 
N-nitrites, mould-infected foods, toxins produced by 
fungi, a deficiency in minerals, infectious processes such 
as fungal and human papilloma virus (HPV), genetic 
susceptibility and an unhealthy lifestyle including the use 
of tobacco and alcohol all increase the risk for 
oesophageal cancer. The use of pesticides, chemical 
fertilisers, and the consumption of contaminated water 
has been linked to the development of oesophageal 
cancer.  
Colorectal cancer and its common risk factors: 
Dietary: There is a strong association between colon 
cancer and nutritional, hereditary and environmental 
factors. The effect of carcinogens and familial hyper-
susceptibility can induce gene mutation leading to cancer 
development. With the marked improvement of living 
standards in China, the Chinese are no longer faced with 
starvation; instead they have an abundance of choices for 
nutrition. There is a significant change in the diet in 
China; high calories, high fat, high protein and less fibre 
now comprise the typical Chinese diet. The unhealthy 
diet and more westernised lifestyle may have contributed 
to the increase of colorectal cancer in China.  
Genetics: Hereditary factor plays a very important 
role in colorectal cancer. It is estimated that 5 to 20% of 
colon cancers may be due to hereditary conditions such 
as hereditary non-polyposis colon cancer (HNPCC), and 
familial adenomatous polyposis (FAP). 
Certain gastrointestinal ailments can also increase 
the risk for colon cancer such as ulcerative colitis, 
Crohn’s disease, and adenomatous polyposis, all of 
which have increased in China.  
THE MANAGEMENT OF LUNG AND BREAST CANCERS IN 
CHINA 
The strategies in the prevention and treatment of lung 
cancer 
1.  Prevention: The single most effective measure 
to reduce lung cancer in China is smoking 
cessation and the elimination of all tobacco 
products in China. This has proven to be 
extremely difficult to accomplish due to various 
historical, cultural, social and economic XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   4 
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influences. A concerted effort has not been 
established by the government to ban smoking. 
2.  Early diagnosis and intervention: Early 
diagnosis and intervention can improve the 
treatment outcome for lung cancer. 
Unfortunately, effective and practical measures 
to screen for lung cancer in China are not 
available. (Or not established?)  
3.  Treatments: 
a.  Minimum invasive treatments such as 
video-assisted thoracoscopy and 
thoracotomy surgery (VATS) and 
radiofrequency ablation (RFA) can be used 
in early stages or highly-selected patients.  
b.  Comprehensive multi-modality therapy 
with a combination of local and systemic 
therapy can maximise the treatment 
outcome for more advanced stage lung 
cancers. Systemic therapy includes 
chemotherapy, targeted therapy and 
rehabilitation.  
c.  Effective health care policy: It is necessary 
to increase governmental funding for the 
prevention, diagnosis and treatment of lung 
cancer. The main focus should be 
curtailing the use of tobacco in China. 
The practice guidelines of lung cancer 
The main treatment modalities for lung cancer are 
surgery, radiation therapy and chemotherapy. More 
recently bio-molecular targeted therapy has been 
incorporated into the comprehensive strategies of lung 
cancer management. In China, there are 58 Positron 
Emission Tomography-Computed Tomography (PET-CT) 
scanners which have played an important role in 
improving lung cancer staging and radiation treatment 
planning.  
Surgery remains the main treatment modality for 
early stage (I-IIb) non-small cell lung cancer (NSCLC). 
Over the last decade there have been significant 
advancements in minimum invasive surgery in China. 
This reduces the risk of surgery in elderly patients and 
those with significant co-morbidities such as chronic 
obstructive pulmonary disease (COPD). Adjuvant 
radiation therapy and/or chemotherapy are used in 
selected patients. For advanced stage NSCLC, 
chemotherapy or supportive care are the treatments of 
choice (table 3).  
Radiation therapy for NSCLC 
Conventional radiation therapy 
The treatment volumes cover the primary with a 
margin of 1.5 – 2cm and ipsilateral hilar and mediastinal 
lymph nodes. The standard treatment has generally been 
1.8 -2 Gy per fraction, one fraction per day, five days per 
week, for a total dose of 40 Gy to 66 Gy. The initial 
volume is treated to a dose of 40 Gy, and then the area of 
residual disease detected on a repeat CT scan will be 
boosted to a total dose of 66 Gy.  
Intensity modulated radiation therapy (IMRT) 
The treatment volume is defined according to ICRU 
50. Gross target volume (GTV) is defined as the known 
volume of the primary tumour and its regional nodal 
metastases clinically and radiologically. GTV will be 
contoured on the lung window of the CT scan. Clinical 
Table 3  Chemotherapy regimens for non-small cell lung cancer 
NSCLC. 
First line 
NP-vinorelbine-vavelbin & platinum  
 Platinum   80 mg/m
2 IV gtt on day 1 
Vinorelbine 25  mg/m
2 IV gtt on day 1,8 
Repeat every 3 weeks 
GP-gemcitabine & platinum   
Platinum 75  mg/m
2 IV gtt on day 2 
Gemcitabine 1250  mg/m
2 IV gtt on day 1,8 
Repeat every 3 weeks 
EP-etoposide (VP-16)& platinum   
Platinum 75  mg/m
2 IV gtt on day 1 
VP-16 120  mg/m
2 IV gtt on day 1,2,3 
Repeat every 3 weeks 
PT-platinum & Paclitaexel 
Paclitaxel 175  mg/m
2 IV gtt day 1 
Platinum 75  mg/m
2 IV gtt on day 1 
Repeat every 3 weeks 
PD-platinum and docetaxel 
Platinum 75  mg/m
2 IV gtt on day 1 
Docetaxel 75  mg/m
2 IV gtt on day 2 
Repeat every 3 weeks 
CPT-11/DDP 
Platinum 60  mg/m
2 IV gtt on day 1 
CPT-11 60  mg/m
2 IV gtt on day 1,8,15 
Repeat every 3 weeks  
PC-paclitaxel & carboplatin (CBP)   
CBP  AUC5 IV gtt on day 1 
Paclitaxel 175  mg/m
2 IV gtt on day 1 
Repeat every 3 weeks 
Second line chemotherapy 
Docetaxel 75  mg/m
2 IV gtt on day 1 
Repeat every 3 weeks 
Pemetrexed   500 mg/m
2 IV gtt on day 1 
Repeat every 3 weeks XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   5 
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target volume (CTV) is defined as GTV plus 1cm margin 
to include surrounding subclinical disease and the area at 
risk for microscopic involvement. The radiologists, 
radiation oncologists and physicists work together to 
define the CTV. Planning target volume (PTV) is CTV 
plus 1.5 cm. PTV is covered by 90% isodose line. Lung 
V20 ≤ 20%. Dose to oesophagus ≤ 40 Gy and to heart 
≤ 30 Gy. Median dose is 64.8 Gy (60 Gy to 72 Gy), 1.8 – 
2 Gy per fraction, one fraction per day and 5 fractions 
per week. 
Targeted therapy 
Several new bio-molecular targeted therapy agents, 
such as gefitinib, erlotinib and bevacizumab, have 
become available in China. 
Small cell lung cancer (SCLC) 
The treatment of small cell lung cancer mainly 
involves chemotherapy. Table 4 shows the most common 
regimens that are used in China. 
Management of Breast Cancer 
Table 5 shows the chemotherapy regimens for breast 
cancer. 
Post-mastectomy radiation therapy 
The radiation target volume post-radical or modified 
radical mastectomy includes chest wall and regional 
lymph nodes. The indication of radiation and the 
identification of target volume are dictated by the stage 
of the primary tumour and regional lymph nodes. 
Chest wall: The upper border is the thoracic 
entrance or to match the lower border of the 
supraclavicular field (half-beam block). The lower 
border is 1-2 cm inferior to the breast tissue. The medial 
border is placed just medial to the inner breast tissue or 
the midline of sternum. The lateral border is the midline 
of axilla. The chest wall post-modified radical 
mastectomy is irradiated using 4 -6 MV x-ray via 
standard tangent fields with wedges and bolus. The chest 
wall post-radical mastectomy is irradiated en-face using 
electrons. The energy of the electrons is selected 
according to the thickness of the chest wall. Bolus is 
used to increase the skin dose to ≥ 85%. The total dose 
will be 45 Gy to 50 Gy.  
Supraclavicular lymphatic drainage: The upper 
border extends laterally across the neck and the trapezius 
to the acromial process. The lower border is at the first or 
Table 4  Most common treatments for small cell lung cancer 
(SCLC) used in China. 
Chemotherapy: 
EP: Etoposide (VP-16) & cisplatin (CDDP)   
CDDP   75 mg/m
2 IV gtt on day 1 
VP-16 100-120  mg/m
2 IV gtt on day 1, 2, 3 
Repeat every 3 weeks 
Other regimens include: 
EC: Etoposide & carboplatin (CBP) 
  
Repeat every 3 weeks 
CDDP & CPT-11   
Repeat every 4 weeks 
Radiation therapy (RT): 
Thoracic RT:  40-50 Gy/4-5 weeks 
Prophylactic whole brain irradiation:  
  30-36 Gy/10-12 fractions/2-2.5 weeks 
Table 5  Chemotherapy regimens for breast cancer. 
CMF 
Cyclophosphomide (CTX)  100 mg/m
2, po, day 1-14 
Methotrexate (MTX)  40 mg/m
2, IV gtt, on day 1, 8 
5-Fu 600  mg/m
2, IV gtt, on day 1, 8 
Every 28 days/cycle 
FAC 
5-Fu 500  mg/m
2, IV gtt, on day 1, 8 
Adriamycin (ADM)  50 mg/m
2, IV on day 1 
CTX 500  mg/m
2 IV on day 1 
Every 21 days/cycle 
AC 
ADM 60  mg/m
2, IV, on day 1 
CTX 600  mg/m
2, IV, on day 1 
Every 21 days/cycle 
TAC 
TXT 75  mg/m
2, IV gtt, on day 1 
ADM 50  mg/m
2, IV gtt, on day 1 
CTX 500  mg/m
2, IV, on day 1 
Every 21 days/cycle 
AC->T 
ADM 60  mg/m
2, IV, on day 1 
CTX 600  mg/m
2, IV, on day 1 
Every 21 days/cycle x 4 cycles 
Paclitaxel 175  mg/m
2 IV gtt, on day 1 
Every 21 days/cycle x 4 cycles 
FEC 
5-Fu 400  mg/m
2, IV gtt, on day 1, 8 
EPI 50  mg/m
2, IV, on day 1, 8 
CTX 500  mg/m
2, IV, on day 1, 8 
Every 28 days/cycle XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   6 
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second intercostal space. The medial border is the 
midline of the sternum or 1 cm beyond. The lateral 
border is the anterior line of axilla. The dose covers a 
depth of 3-4 cm. The mixed beams of photons (
60Co or 
4-6 MV x-ray) and electrons (12 MeV) are used to 
deliver 45 – 50 Gy in conventional fractionation. 
Internal mammary chain: The upper border is at the 
medial head of clavicle or to match the lower border of 
the supraclavicular field. The lower border is in the 
fourth intercostal space. For a primary tumour located at 
the inner lower quadrant, the lower border is at the sixth 
intercostal space. The medial border is the midline of 
sternum or 1 cm beyond. The lateral border is 5 cm from 
the midline of sternum to the ipsilateral chest wall. The 
dose covers a depth of 3-5 cm. Electrons with 
appropriate energy are used to deliver 45 – 50 Gy in 
conventional fractionation. 
Axillary lymphatic drainage: The upper border is at 
the clavicle. The lower border is at the second intercostal 
space. The medial border is 1-1.5 cm lateral to the chest 
wall. The lateral border is at the posterior line of the 
axilla. The 4-6 MV x-ray is used to deliver 45 – 50 Gy in 
conventional fractionation. 
Post-lumpectomy radiation therapy 
Tangential fields and boost fields: The borders of 
the tangential fields are usually defined as follows: 
medial border is midline of the sternum (or 3 cm beyond 
midline to include the internal mammary chain); lateral 
border is mid-axillary; inferior border is 1-2 cm below 
the breast; superior border is the thoracic entrance or to 
match the inferior border of the supraclavicular field. 
The total dose is 45-50 Gy at 1.8 -2 Gy per fraction, 
5 fractions a week.  
Accelerated partial breast irradiation: There are 
many ways to deliver partial breast irradiation either with 
brachytherapy including; interstitial brachytherapy, 
intracavitary brachytherapy or an external beam radiation 
therapy system such as a 3D Conformal radiotherapy or 
IMRT and intraoperative radiotherapy (IORT). 
Hormone therapy for breast cancer 
Hormone therapy is commonly used for patients 
with breast cancer that stain positive for oestrogen 
receptor (ER) and progestron receptors (PR). Targeted 
therapy such as trastuzumab is used for Her2 receptor 
positive patients respectively. 
CURRENT STATUS OF RADIATION ONCOLOGY IN CHINA 
Radiotherapy Equipment in China 
There is a significant shortage in radiotherapy 
equipment to meet the increasing needs in China. As of 
September 2006, there were 952 radiation therapy 
centers that were equipped with 918 linear accelerators, 
472 
60Co machines, 146 ortho-voltage x-ray machines, 
827 fluoroscoopy simulators, and 400 brachytherapy 
units including 21 
252Cf neutron remote afterloading 
brachytherapy units. There were 851 treatment planning 
systems and 467 ion-chambers [10]. In comparison to the 
1997 survey, there has been a 321% increase in linear 
accelerators and 481% increase in treatment planning 
systems. As of 2006, there were 214 CT simulators, 149 
Gamma Knives (74 for head only, 75 for both head and 
body), and 467 X-Knife machines. Despite the 
significant growth in radiation oncology equipment, 
there is less than 1 (0.7) accelerator per million people. 
Even considering both 
60Co machines and linear 
accelerators combined, there are only 1.06 machines per 
one million population, which is short of meeting the 
minimum requirements of the World Health 
Organization of two linear accelerators per million 
population. The radiotherapy equipment is also unevenly 
distributed throughout the country. In the major cities or 
provinces such as Beijing, Shanghai, and Shandong, 
there are at least two machines per million people, 
whereas in more remote regions of China such as deep 
inland and the western part of the country, there is 
limited accessibility to radiotherapy equipment.  
Radiation Technique 
The majority of radiation centers in China are 
equipped and capable of performing basic three 
dimensional conformal radiotherapy (3D-CRT) as 
reported by the 2006 survey [10]. Among 952 registered 
radiation centers in China, 579 centres (60%) were 
practising three-dimensional conformal radiotherapy, but 
only 115 (12%) were delivering intensity-modulated 
radiotherapy (IMRT). Approximately 8% of centres were 
capable of doing stereotactic radiosurgery [10].  
Radiation Oncologists and Radiation Physicists in China 
There are 18,992 healthcare workers that are 
involved in providing radiation therapy in China. Among 
them, 5,247 are radiation oncologists (including 2,110 
residents), 4,559 radiation therapists, 6,864 nurses, 1,181 
medical physicists, and 1,141 are maintenance engineers. 
Clearly there is a severe shortage in medical physicists. 
Radiation Therapy Funding in China 
In China, there is a significant lack of funding and 
reimbursement to maintain costly radiotherapy 
equipment and meet the demands. A national health 
insurance system in China has not been developed. The 
reimbursement rates for cancer treatment are set by the 
local governments and vary widely due to the differences 
in the financial situations of each district. For example, 
in City of Qingdao the municipal healthcare agency 
reimburses 80% for IMRT treatment. However, at the 
same time they also set a fixed reimbursement rate of 
250 Chinese yuan (equivalent to approximately $40) for 
each IMRT beam, 80% of which will be reimbursed. The 
government will only pay 70% of the radiation treatment 
planning cost. The rest of the expense has to be paid by 
the patients. For 3D-CRT the local government has set 
the maximum reimbursement rate of 1,100 yuan 
(equivalent to approximately $150). Therefore, a XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   7 
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significant portion of the expense will have to be paid by 
the patients or they have to accept substandard or no 
treatment at all. The same situation also applies to 
chemotherapy treatments. The government will pay the 
full amount of money, but only for the basic drug 
regimen. However, the newer or more expensive 
chemotherapy drugs (which may be more effective) will 
get little or no reimbursement. Furthermore, 60% of the 
Chinese population have no medical insurance or 
coverage at all. Unfortunately for those patients, they 
either have to pay completely out-of-pocket (which very 
few can afford), or settle for less service, which 
oftentimes results in inadequate healthcare. As most 
people either have no healthcare insurance or have an 
insurance coverage with low reimbursement rates, it is 
very difficult, if not impossible, for them to receive 
comprehensive or long-term care. There is also a 
profound disparity of healthcare within China. In eastern 
regions of China, especially large coastal cities, medical 
care is more advanced and relatively accessible than that 
in remote areas such as many western provinces. 
UNIQUE CANCER THERAPY IN CHINA 
China has a long history of using its traditional 
Chinese medicine for various ailments, including 
malignancies. Clinical and experimental research have 
shown that Chinese medicine may have positive effects 
on cancer and cancer therapy. The potential benefits of 
traditional Chinese medicine are believed to be as 
follows: 
1.  Reducing the toxic side-effects of 
chemotherapy and radiation therapy. 
2.  Improving human immune systems and its 
functions. 
3.  Improving haematopoiesis in bone marrow.  
4.  Improving endocrine function and body 
metabolism 
5.  Re-establishing homeostasis to promote the 
human body’s recovery. 
6.  Enhancing the treatment effects which may lead 
to a prolonged survival. 
Qigong 
 Qigong (an ancient Chinese exercise system of deep 
breathing) is also believed to improve a patient’s overall 
well-being by adjusting each organ’s function. It further 
improves the patient’s immune system and boosts one’s 
confidence.  Qigong may also perk up a patient’s 
emotional and psychological state of health leading to a 
better tolerance of cancer therapy and a faster recovery. 
Incorporating Chinese medicine into a 
comprehensive cancer treatment program may enhance 
the overall treatment outcomes. In recent years, the 
Chinese government has approved the use of some 
Chinese herbal remedies that may improve the immune 
function of cancer patients and also may have additive 
effects to conventional cancer therapy. 
Chinese Herbal Medicine 
Chinese herbal medicine has existed and been 
practised in cancer therapy in China for ages. It is 
administered based on the underlying physio-pathologic 
processes of the malignancies, including the type and 
stage of the malignancy, the patients’ overall state of 
health and nutritional status. Chinese medicine remedies 
also take other treatment modalities into consideration 
such as the side-effects from the treatment (e.g. 
chemotherapy or radiation) and clinical symptoms. It is 
believed that Chinese herbal medicine may lessen the 
patient’s clinical symptoms, decrease toxic side-effects 
from conventional western approaches and result in 
favourable therapeutic ratios. The use of Chinese herbal 
medicine is a very complicated process that contains the 
art and science of medicine as well as human experiences, 
wisdom, and knowledge that have been accumulated and 
passed on for generations in China. The combination of 
conventional western medicine and traditional Chinese 
medicine may be complementary to each other and may 
ultimately improve the cancer care in China. 
252Cf neutron remote afterloading brachytherapy 
China has a relatively large number of remote 
afterloading neutron brachytherapy units using 
Californium-252 (
252Cf) nuclide which is a source of 
gamma neutron radiation. 
252Cf generated by nuclear 
reactions produces fast neutrons which offer high-LET 
radiation and potentially a more effective cell kill effect 
than photons. The indication and technique of 
252Cf are 
similar to those that are used with 
192Ir for treating intra-
cavitary/intra-luminal or body surface tumours such as 
oesophageal and cervical cancer. 
252Cf is, at least 
theoretically, equal to or more effective than photons 
generated by 
192Ir. Because of its high-LET radiation 
252C 
may offer more favourable treatment outcomes for 
tumours that have large hypoxic cell population or 
tumours that did not respond to conventional photon 
radiation. For difficult or recurrent tumours with hypoxic 
cells, 
252Cf neutron therapy may also produce a faster 
tumour response compared to that of photon beam. 
Dendritic Cell Immunotherapy 
China has a very active program in basic and 
clinical research on dendritic cell immunotherapy. A new 
and more efficient way to culture LAK cells was 
developed in China. This allowed a more efficient way to 
produce LAK cells for possible clinical use. This new 
approach was used in a clinical trial using cultured 
CD3AK cells in 1999. This therapy has the following 
advantages: 1) it can be used for a wide range of 
malignancies, 2) it has significant effects on both 
primary tumours and metastases, 3) it may be more 
effective than conventional chemotherapy in adjuvant 
setting, and 4) the side effects are mild (only low-grade 
fevers). Based on early clinical evidence, this new 
modality appeared to be more efficacious when 
combined with chemotherapy to treat advanced stage 
cancers. The tumour response rate has been reported to XJ Ma et al. Biomed Imaging Interv J 2008; 4(3):e39   8 
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be as high as 60%. It was the first time that the DC + 
CIK was combined with chemotherapy to treat late stage 
lung cancer and combined with neutron knife to treat 
colon cancer in clinical trials conducted in China. Further 
research and larger clinical trials are being done in this 
area.  
THE HEALTHCARE POLICIES 
China is experiencing a rapid growth in the aging 
population and cancer incidence. In the past, the 
government health agencies were focused more on 
cancer treatment than its prevention. Recently the 
Chinese government has started to attribute more 
attention towards cancer prevention and cancer therapy 
rehabilitation. Fortunately, the basic needs for surgical 
oncology equipment have been met and many radiation 
therapy facilities have been developed in the last 
20  years. More and more linear accelerators and 
60Co 
machines have been installed nationwide. But it is far 
from meeting the basic needs in China. Chemotherapy is 
also advancing and has adopted the international 
standards in many parts of China. The concept and 
practice of terminal care have also been introduced into 
more families, healthcare institutions and social welfare 
organisations in today’s practice. The government has 
also allowed more use of narcotics for pain control for 
terminal cancer patients. As an example, the city of 
Qingdao was one of the first cities in the nation to start 
an education centre for cancer patients which is 
supported by the local government. The centre is open to 
the public. It provides guidance and assistance on a wide 
range of issues in cancer care and cancer therapy 
rehabilitation. The centre also provides telephone 
hotlines for psychological counseling for cancer patients. 
Patient support groups meet regularly to discuss the 
variety of issues that they are facing, including cancer 
therapy, the coping process and rehabilitation. 
Oncologists are invited to give lectures and advice to the 
participating groups.  
The central government has realised that the cost of 
cancer treatment is overwhelming and will continue to 
grow exponentially in the foreseeable future. The best 
way to curtail the cost in cancer care is cancer prevention. 
The current health insurance system provided by the 
local government does not provide funding for 
preventive measures, which has been a major obstacle to 
the implementation of preventive medicine. Since 2004, 
the Chinese government has made efforts to increase 
funding for cancer prevention and early detection which 
are important to reducing cancer-related deaths in China. 
Multidisciplinary management has become the principle 
of cancer treatment, and efforts to practise the standard 
of care have been implemented. However, there remains 
a large number of Chinese people who do not have 
health insurance or have coverage that is inadequate as 
the cost extends beyond their financial ability to even 
afford the co-pay. Therefore, cancer patients are facing 
heavy financial burdens which may prevent them from 
obtaining little, if any, cancer therapy. These problems 
are much more profound in the rural areas of China.  
THE FUTURE CHALLENGES 
Cancer care is a complicated process that requires an 
enormous effort and resources from the government, 
healthcare workers and cancer researchers. It is estimated 
that 80% of cancers are preventable; therefore, it is 
essential to control environmental pollution and to 
advocate a healthy lifestyle and diet. An increase in the 
awareness of cancer prevention and early detection 
through educating the public has become paramount. It is 
absolutely necessary for both the central and local 
governments to greatly increase the funding for cancer 
care and to improve the distribution of the resources 
throughout China. 
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